Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said it has been designated as a top research site for MindMed Inc's (NASDAQ:MNMD, NEO:MMED) Phase 2b study on MM-120 (lysergide D-tartrate) for General Anxiety Disorder.
The company's Cedar Clinical Research (CCR), located in Draper, Utah, has emerged as the leading site for the study, having successfully enrolled and dosed 19 clinical trial participants thus far. Additionally, CCR has recently initiated the recruitment of volunteers for the trial at a second research clinic in Murray, Utah.
Paul Thielking, the chief science officer at Numinus and principal investigator at CCR Murray, expressed enthusiasm about the collaboration with MindMed.
In a statement, he commented: "We're excited to support MindMed in their clinical trial work, by evaluating new important treatments and protocols to address mental health disorders. The fact that our Draper research clinic is the top enrolling site for the study underscores the quality of our clinical research capabilities and recruiting efforts."
MindMed's study plans to enroll a total of 200 participants who will receive either a single administration of MM-120 at varying doses (25 µg, 50 µg, 100 µg, or 200 µg) or a placebo. Topline results are anticipated to be released by the company in late 2023.
MindMed specializes in the development of innovative products for the treatment of brain health disorders, particularly focusing on psychiatry, addiction, pain, and neurology. The company is actively building a pipeline of groundbreaking drug candidates targeting the serotonin, dopamine, and acetylcholine systems, with and without acute perceptual effects.
Numinus Wellness plays a vital role in advancing mental health care and providing access to evidence-based psychedelic-assisted therapies.
Contact the author at jon.hopkins@proactiveinvestors.com